Rep. Kevin Hern Sells Kenvue Inc. (NYSE:KVUE) Shares

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Kenvue stock on March 17th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.

Kenvue Price Performance

Shares of KVUE stock opened at $17.30 on Tuesday. The stock has a market cap of $33.15 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 3.89 and a beta of 0.61. The business’s fifty day moving average is $17.98 and its 200 day moving average is $17.07. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.26 earnings per share. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Institutional Investors Weigh In On Kenvue

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Kenvue by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after buying an additional 1,604,040 shares during the last quarter. State Street Corp boosted its position in shares of Kenvue by 3.5% during the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock valued at $2,050,424,000 after buying an additional 4,063,257 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Kenvue by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after buying an additional 371,322 shares during the last quarter. Independent Franchise Partners LLP boosted its position in shares of Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after buying an additional 17,343,785 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Kenvue during the fourth quarter valued at $756,862,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KVUE shares. Citigroup increased their target price on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Friday, March 6th. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $19.58.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.